Mayo Clinic Archives - Medical Design Sourcing

SimBioSys, Mayo Clinic partner on AI-powered tech for breast cancer patients

SimBioSys announced today that it entered into a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions.

The collaboration aims to develop cloud-based clinical software to support end-to-end decision-making for early-stage breast cancer patients. This includes individualized surgical planning, treatment, drug selection and risk stratification.

As part of the collaboration, SimBioSys has had access to and has analyzed data from patients participating in the Mayo Clinic-led BEAUTY clinical trial. The company uses AI and data science to unlock spatial biophysical insights to help clinicians tailor treatment plans for each patient.

SimBioSys plans to perform simulations using previously acquired data. While validating the platform’s predictive accuracy, it also expects to perform in-silico scenario analysis guided by the Mayo team.

The company offers its TumorSight cloud-based platform for use during the treatme…

Mayo Clinic is using Asensus surgical robotics for pediatric cases

The Intelligent Surgical Unit powers the Senhance surgical robot system. [Image courtesy of Asensus Surgical]Asensus Surgical (NYSE:ASXC) named Mayo Clinic as the previously unidentified hospital customer that has leased the company’s surgical robotics system for pediatric cases.

The Mayo Clinic Hospital at the Saint Marys Campus in Rochester, Minnesota, is already using the Asensus Senhance system for pediatric operations, the device developer said in a recent regulatory filing.

Research Triangle Park, North Carolina-based Asensus said in July that the deal made Senhance the first system exclusively utilized by pediatric surgeons at any U.S.-based hospital. The device developer named Mayo Clinic in a three-sentence filing with the Securities and Exchange Commission last month.

Rochester-based Mayo Clinic also uses Intuitive Surgical’s da Vinci system at various locations across its hospital network.

Asensus (formerly called TransEnterix)…

Anumana wins FDA clearance for ECG-AI algorithm

Screen shot of sample data from Anumana’s ECG-AI LEF. [Image courtesy of Anumana]Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.

Cambridge, Massachusetts-based Anumana, an Nference portfolio company, worked in collaboration with Mayo Clinic. They designed the breakthrough medical device to detect low ejection fraction (LEF) in patients at risk of heart failure. The company’s pulmonary hypertension (PH) early detection algorithm also won FDA breakthrough device designation last year.

Developed as software-as-a-medical device (SaMD), the algorithm screens LEF in adults at risk for heart failure. It uses data from a routine 12-lead electrocardiogram (ECG). Anumana developed it using research from Mayo Clinic that included more than 100,000 ECG and echocardiogram data pairs. The data came from more than 25 studies evaluating more than 40,000 patients in the U.S. and abroad.

Further data from 16,0…

GE HealthCare, Mayo Clinic partner on medical imaging, theranostics

Mayo Clinic and GE HealthCare (Nasdaq: GEHC) + today announced a strategic collaboration aimed at improving radiology practice and therapy delivery.

It marks the second collaboration between GE HealthCare and a major hospital this month alone. Last week, the company announced an AI-focused partnership with Massachusetts General Hospital.

The Strategic Collaboration for Innovation in Medical Imaging and Theranostics covers research and product development programs. It includes Mayo Clinic and GE HealthCare scientists, technology developers, clinicians and other healthcare providers.

Mayo Clinic and GE HealthCare aim to better equip clinicians with technology to precisely diagnose and treat medical conditions. They want to personalize the patient experience at each step of the care journey, according to a news release. Mayo and GE HealthCare said they seek to translate novel technologies and approaches to medical …

Mayo Clinic takes a stake in PillBot developer Endiatx

Endiatx co-founder and CEO Torrey Smith with PillBot [Photo by Hardy Wilson for MDO]Mayo Clinic and Endiatx have signed a know-how license agreement covering the ongoing development of Endiatx’s PillBot.

The deal gives Mayo Clinic an equity stake in the robotic stomach camera startup, Endiatx co-founder and CEO Torrey Smith told MassDevice. He declined to share the precise size of the single-digit percentage equity stake or other financial terms, but said no cash was changing hands.

Dr. Vivek Kumbhari [Photo courtesy of Dr. Kumbhari]The agreement formalizes Hayward, California-based Endiatx’s collaboration with Rochester, Minnesota-based Mayo Clinic. Dr. Vivek Kumbhari, the chair of gastroenterology and hepatology at Mayo Clinic–Florida, joined the Endiatx board in 2021.

The agreement is set to remain in place for a few years, which Smith said he hoped would be enough time to get a fully developed PillBot through a clinical trial and onto the marke…

BD, Mayo Clinic team up to improve patient care

BD (NYSE:BDX) announced today that it will collaborate with Mayo Clinic Platform to perform detailed post-market surveillance.

Franklin Lakes, New Jersey-based BD’s collaboration with Mayo Clinic Platform will access de-identified patient data from the Mayo Clinic Platform_Discover to perform post-market surveillance on the company’s products and fuel innovation, unlocking a faster, more efficient path to market with the overarching goal of improving patient care.

According to a news release, Mayo Clinic Platform_Discover represents a robust de-identified data set available from 10 million patients, including both structured and unstructured data, images, 1.2 billion lab test results, 3 million echocardiograms and more than 640 million clinical notes.

BD intends to use the platform’s capabilities in data mining, next-generation artificial intelligence (AI) and machine learning tools to analyze real-world data to generate insight into th…

Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension

Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm.

Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in 2021, designed its AI-enhanced, electrocardiograph (ECG)-based PH early detection algorithm as a precise, non-invasive screening tool to provide earlier diagnosis for patients with PH that may otherwise go unnoticed until the disease has advanced.

The algorithm leverages 12-lead ECGs and is enabled by the nference platform that provides insight from more than 6 million de-identified patient records, including over 8 million ECGs. It analyzes the voltage-time data and within seconds provides a prediction of the likelihood of PH, reducing the time between initial symptoms and the first evaluation for PH via targeted cardiac imaging.

According to a news release, the algorithm was developed through a collaboration between data scie…

gBETA Medtech accelerator picks its next startups

The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day.

“We’re so fortunate to have such a diverse set of founders with expertise across the healthcare continuum,” gBETA Medtech Director KC Caine said in a news release. “Our founders are bringing high-impact innovations to the sector, and we’re excited to see how their companies grow.”

gBETA is a program of startup accelerator Gener8tor and the University Enterprise Labs business incubator in St. Paul, Minnesota, with mentorship support from Mayo Clinic, the University of Minnesota and Medical Alley Association. The program’s founding sponsor is Boston Scientific; UEL and Gener8tor also get support through a cooperative agreement with BARDA DRIVe.

Get the full story at our sister site, Medical Design & Outsourcing.

Mayo Clinic’s new Apple Watch app uses AI to detect left-ventricular dysfunction

The Mayo Clinic developed a new app that transmits ECG signals from Apple Watches for AI analysis to identify heart disease.

The application transmits ECG (electrocardiograms) signals recorded in non-clinical environments seamlessly and securely to a medical center so that the AI analysis can identify left-ventricular dysfunction, a life-threatening, asymptomatic heart disease.

According to a news release, a study — for which results were presented as late-breaking clinical science during Heart Rhythm 2022 — observed 2,454 subjects from 46 states and 11 countries who downloaded the study app for their Apple Watch. The average age was 53±15 years and 56% were female.

Mayo Clinic’s app sent all previously recorded ECGs for clinician review and AI analyzed ECGs acquired within one month of a clinically ordered ECG. They were evaluated for the presence of ejection fraction ≤40% using a model adapted for single lead use.

“We have seen how artific…

This CEO is swallowing his own devices to fund his swimming PillBot

Endiatx co-founder and CEO Torrey Smith with PillBot in his Oakland, California, workshop [Photo by Hardy Wilson for MDO]As he prepared to swallow his robot for the first time, Torrey Smith’s doctors warned that the battery was his greatest threat.

If the capsule came apart and the battery burned the tissue lining his stomach, it would only be the beginning of a very bad experience.

“I was just hoping that we would get any kind of a positive signal that we were on the right track,” Smith, co-founder and CEO of Endiatx, said of the June 2020 test. “At that time, our radio bandwidth was so limited. We were pushing 48 pixels square of grayscale, not even color, at just a few frames per second. The worst video quality you could imagine — but it was real.”

The PillBot prototype’s inaugural journey into Smith’s gastrointestinal tract was a success, beaming live footage from his stomach without anesthesia, sedation, recovery time or air pumped into his gut to infl…

Deadline nears for gBETA Medtech startup accelerator

The gBETA program for medtech startups is seeking applicants from across the globe on or before March 14 for its spring session.

The seven-week gBETA Medtech virtual accelerator runs April 18 through June 14. gBETA is a program of startup accelerator Gener8tor and the University Enterprise Labs business incubator in St. Paul, Minnesota, with support from Mayo Clinic, the University of Minnesota, Medical Alley Association and founding sponsor Boston Scientific.

Up to five startups will be selected for the medtech program, which covers medical devices, diagnostics, healthcare software, biotechnology, drug discovery and delivery and more.

Get the full story at our sister site, Medical Design & Outsourcing.

Mayo Clinic helps launch two new companies for improved diagnostics

Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched.

Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release.

“The dramatically increased use of remote patient telemetry devices coupled with the rapidly accelerating development of AI and machine learning algorithms has the potential to revolutionize diagnostic medicine,” Mayo Clinic Platform president Dr. John Halamka said in the release. “With RDMP, clinicians will have access to best-in-class algorithms and care protocols and will be able to serve more patients effectively in remote care settings. The platform will also enable patients to take more control of their health and make better decisions based on insights delivered directly to them.”